Official Japanese guidelines for the use of infliximab for rheumatoid arthritis

Nobuyuki Miyasaka, Tsutomu Takeuchi, Katsumi Eguchi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Differences in ethnic backgrounds as well as in medical and socioeconomic status often affect both the efficacy and adverse effects of medications. Recent data suggest an increased risk of opportunistic infections, especially tuberculosis (TB), among rheumatoid arthritis (RA) patients receiving infliximab, a chimeric monoclonal anti-tumor necrosis factor α (TNF-α) antibody. In this regard, the annual incidence of TB is approximately five times higher in Japan than in the United States. Furthermore, since Bacillus Calmette-Guérin vaccination is mandatory in childhood when the skin test for purified protein derivative (PPD) is negative, a high incidence of false-positive PPD skin tests is observed among the Japanese population. In addition, the upper limit of methotrexate dosage to be used for RA is lower in Japan. We have therefore established official guidelines for the proper use of infliximab in Japanese RA patients. In this review, an algorithm for the diagnosis and management of TB in RA is presented in an evidenced-based form.

Original languageEnglish
Pages (from-to)4-8
Number of pages5
JournalModern Rheumatology
Volume15
Issue number1
DOIs
Publication statusPublished - 2005 Feb
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Guidelines
Tuberculosis
Skin Tests
Japan
Incidence
Opportunistic Infections
Methotrexate
Social Class
Bacillus
Vaccination
Proteins
Tumor Necrosis Factor-alpha
Infliximab
Antibodies
Population

Keywords

  • Guideline
  • Infliximab
  • Rheumatoid arthritis (RA)
  • Tuberculosis (TB)
  • Tumor necrosis factor α (TNF-α)

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. / Miyasaka, Nobuyuki; Takeuchi, Tsutomu; Eguchi, Katsumi.

In: Modern Rheumatology, Vol. 15, No. 1, 02.2005, p. 4-8.

Research output: Contribution to journalArticle

Miyasaka, Nobuyuki ; Takeuchi, Tsutomu ; Eguchi, Katsumi. / Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. In: Modern Rheumatology. 2005 ; Vol. 15, No. 1. pp. 4-8.
@article{9300619043134d8a8c0a52237fcf3cb4,
title = "Official Japanese guidelines for the use of infliximab for rheumatoid arthritis",
abstract = "Differences in ethnic backgrounds as well as in medical and socioeconomic status often affect both the efficacy and adverse effects of medications. Recent data suggest an increased risk of opportunistic infections, especially tuberculosis (TB), among rheumatoid arthritis (RA) patients receiving infliximab, a chimeric monoclonal anti-tumor necrosis factor α (TNF-α) antibody. In this regard, the annual incidence of TB is approximately five times higher in Japan than in the United States. Furthermore, since Bacillus Calmette-Gu{\'e}rin vaccination is mandatory in childhood when the skin test for purified protein derivative (PPD) is negative, a high incidence of false-positive PPD skin tests is observed among the Japanese population. In addition, the upper limit of methotrexate dosage to be used for RA is lower in Japan. We have therefore established official guidelines for the proper use of infliximab in Japanese RA patients. In this review, an algorithm for the diagnosis and management of TB in RA is presented in an evidenced-based form.",
keywords = "Guideline, Infliximab, Rheumatoid arthritis (RA), Tuberculosis (TB), Tumor necrosis factor α (TNF-α)",
author = "Nobuyuki Miyasaka and Tsutomu Takeuchi and Katsumi Eguchi",
year = "2005",
month = "2",
doi = "10.1007/s10165-004-0357-7",
language = "English",
volume = "15",
pages = "4--8",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Official Japanese guidelines for the use of infliximab for rheumatoid arthritis

AU - Miyasaka, Nobuyuki

AU - Takeuchi, Tsutomu

AU - Eguchi, Katsumi

PY - 2005/2

Y1 - 2005/2

N2 - Differences in ethnic backgrounds as well as in medical and socioeconomic status often affect both the efficacy and adverse effects of medications. Recent data suggest an increased risk of opportunistic infections, especially tuberculosis (TB), among rheumatoid arthritis (RA) patients receiving infliximab, a chimeric monoclonal anti-tumor necrosis factor α (TNF-α) antibody. In this regard, the annual incidence of TB is approximately five times higher in Japan than in the United States. Furthermore, since Bacillus Calmette-Guérin vaccination is mandatory in childhood when the skin test for purified protein derivative (PPD) is negative, a high incidence of false-positive PPD skin tests is observed among the Japanese population. In addition, the upper limit of methotrexate dosage to be used for RA is lower in Japan. We have therefore established official guidelines for the proper use of infliximab in Japanese RA patients. In this review, an algorithm for the diagnosis and management of TB in RA is presented in an evidenced-based form.

AB - Differences in ethnic backgrounds as well as in medical and socioeconomic status often affect both the efficacy and adverse effects of medications. Recent data suggest an increased risk of opportunistic infections, especially tuberculosis (TB), among rheumatoid arthritis (RA) patients receiving infliximab, a chimeric monoclonal anti-tumor necrosis factor α (TNF-α) antibody. In this regard, the annual incidence of TB is approximately five times higher in Japan than in the United States. Furthermore, since Bacillus Calmette-Guérin vaccination is mandatory in childhood when the skin test for purified protein derivative (PPD) is negative, a high incidence of false-positive PPD skin tests is observed among the Japanese population. In addition, the upper limit of methotrexate dosage to be used for RA is lower in Japan. We have therefore established official guidelines for the proper use of infliximab in Japanese RA patients. In this review, an algorithm for the diagnosis and management of TB in RA is presented in an evidenced-based form.

KW - Guideline

KW - Infliximab

KW - Rheumatoid arthritis (RA)

KW - Tuberculosis (TB)

KW - Tumor necrosis factor α (TNF-α)

UR - http://www.scopus.com/inward/record.url?scp=14544304999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544304999&partnerID=8YFLogxK

U2 - 10.1007/s10165-004-0357-7

DO - 10.1007/s10165-004-0357-7

M3 - Article

VL - 15

SP - 4

EP - 8

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -